At the ACR Convergence 2024 Year in Review lecture, experts discussed advancements in disease understanding and treatments, as well as in basic science.
Top Research in Gout from ACR Convergence 2024 at a Glance
Dr. Lisa Stamp helps filter the noise to get to the key insights from the research abstracts on gout presented at ACR Convergence 2024.
Better Education on Gout
Experts addressed how education and follow-up for patients with gout can improve disease management and highlighted the need for a better construction of gout remission.
Lubricin/CD44/PP2A Pathway Offers New Therapeutic Targets for Patients with Gout
Dr. Khaled Elsaid discussed synovial macrophages/monocytes and monosodium urate crystal interactions at a session during ACR Convergence, exploring potential new gout pharmacology targets via the lubricin/CD44/protein phosphatase 2A (PP2A) pathway.
Progress in Gout Education & Remission
An ACR Convergence 2024 session will discuss strategies to educate patients about their disease and review the progress toward the concept of remission in gout to better guide physicians.
Novel Mechanisms of Gout Explored
In a session at ACR Convergence 2024, expert panelists with go into depth concerning molecular mechanisms that contribute to gout pathogenesis.
Your Gout Guide for ACR Convergence 2024: Dr. Lisa Stamp
Lisa Stamp, MBChB, PhD, is here to help the busy clinician by curating a collection of the most significant and notable abstracts in gout research to be presented at ACR Convergence 2024.